The New England journal of medicine 2017-02-02
Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer.
Abstract
Background
Salvage radiation therapy is often necessary in men who have undergone radical prostatectomy and have evidence of prostate-cancer recurrence signaled by a persistently or recurrently elevated prostate-specific antigen (PSA) level. Whether antiandrogen therapy with radiation therapy will further improve cancer control and prolong overall survival is unknown.
Methods
In a double-blind, placebo-controlled trial conducted from 1998 through 2003, we assigned 760 eligible patients who had undergone prostatectomy with a lymphadenectomy and had disease, as assessed on pathological testing, with a tumor stage of T2 (confined to the prostate but with a positive surgical margin) or T3 (with histologic extension beyond the prostatic capsule), no nodal involvement, and a detectable PSA level of 0.2 to 4.0 ng per milliliter to undergo radiation therapy and receive either antiandrogen therapy (24 months of bicalutamide at a dose of 150 mg daily) or daily placebo tablets during and after radiation therapy. The primary end point was the rate of overall survival.
Results
The median follow-up among the surviving patients was 13 years. The actuarial rate of overall survival at 12 years was 76.3% in the bicalutamide group, as compared with 71.3% in the placebo group (hazard ratio for death, 0.77; 95% confidence interval, 0.59 to 0.99; P=0.04). The 12-year incidence of death from prostate cancer, as assessed by means of central review, was 5.8% in the bicalutamide group, as compared with 13.4% in the placebo group (P<0.001). The cumulative incidence of metastatic prostate cancer at 12 years was 14.5% in the bicalutamide group, as compared with 23.0% in the placebo group (P=0.005). The incidence of late adverse events associated with radiation therapy was similar in the two groups. Gynecomastia was recorded in 69.7% of the patients in the bicalutamide group, as compared with 10.9% of those in the placebo group (P<0.001).
Conclusions
The addition of 24 months of antiandrogen therapy with daily bicalutamide to salvage radiation therapy resulted in significantly higher rates of long-term overall survival and lower incidences of metastatic prostate cancer and death from prostate cancer than radiation therapy plus placebo. (Funded by the National Cancer Institute and AstraZeneca; RTOG 9601 ClinicalTrials.gov number, NCT00002874 .).
Related Questions
How will the results of NRG GU006 and the use of the PAM50 genomic classifier impact treatment for recurrent prostate cancer?
Top line results: The prostate cancer-adapted PAM50 gene expression biomarker was validated in the NRG GU006 randomized trial to predict the differential benefit of hormone therapy, specifically apalutamide monotherapy, for patients with recurrent prostate cancer after radical prostatectomy being tr...
Given results of the RADICALS trials, is LT-ADT standard of care for salvage prostate RT?
I do not think long-term ADT is established as standard of care for salvage prostate radiation, as this would require a demonstration of improved overall survival in at least specific subgroups of patients. RADICALS-HD demonstrates improvement in freedom from metastasis as well as freedom from non-p...
Is there any evidence for combining surgery and XRT +/- ADT for treatment of localized high risk prostate cancer?
Presumably, this is a question inquiring about planned post-operative RT. If so, surgery followed by adjuvant, post-operative radiation therapy (PORT) has been profiled extensively in several RCTs: EORTC 22911, SWOG 8794, ARO 96-02, FinnProstataX. The two more recent trials, ARO 96-02 and FinnProsta...
Given RADICALS-HD, are you completing 24 mo vs 6 mo of ADT with XRT following RP?
Initial: We know 2 years of ADT works. Adding to the classic RTOG 9601, RADICALS-HD demonstrated an improvement in the primary and clinically-relevant endpoint of MFS.Who should be offered 2 years is a more nuanced question. I rely heavily on the PSA to guide as I am influenced by the significant in...
How exactly would you utilize ADT via leuprolide or bicalutamide with salvage RT post prostatectomy with PSA >0.5?
The dilemma on the need for hormonal therapy in the salvage radiation setting after radical prostatectomy is a major one in current clinical practice, driven by the modest survival benefits seen in the RTOG 9601 trial with 2 years of bicalutamide (Shipley et al., PMID 28146658), but also follow up s...
Do you consider tertiary grade pattern, LVI or PNI on prostatectomy specimens as adverse features to recommend EBRT and ADT for patients with unfavorable intermediate prostate CA after prostatectomy with undetectable PSA?
No, I don’t think there is any current available evidence to define a benefit for ADT in the post-operative setting for patients with an undetectable PSA. The two major trials which define a benefit for ADT in this setting, RTOG 9601 and GETUG AFU-16 had a lower limit of a PSA of 0.2 at treatment in...
Would you recommend ADT in a patient receiving salvage post-prostatectomy radiation with PSA <0.5 and a high Decipher score?
Certainly, this is an area of evolving management. Here’s what we know about the use of ADT in the salvage setting: RTOG 9601: 2 years of bicalutamide improved 12y OS but PSA at the time of salvage was a significant interaction term with PSA <0.7 receiving no benefit. 2 years of bicalutamide was ass...
What are the current recommendations for androgen blockade for patients undergoing salvage radiation after prostatectomy with PSAs between 0.6 and 1.5?
Just be a little careful here. Although Dr. Spratt did an amazing analysis and thorough presentation of the subgroups, one shouldn't look at PSA <=0.6 as a "cutoff". As Dr. Spratt pointed out in his presentation, the population on RTOG 9601 was mixed in terms of prognostic features.. Would you reall...
Does the presence of interstitial cystitis disease affect your decision to offer post prostatectomy salvage radiation therapy?
The existence of pre-existing interstitial cystitis does not change my recommendations for 1) the need for salvage RT, or 2) the dose/volume. Certainly this man would not be ideal for adjuvant post-operative RT, but with the results of RADICALS and RAVES, adjuvant post-operative RT should be offered...
How do I convince urologists to send patients for a discussion of adjuvant radiation after prostatectomy?
Howard's advice is spot on as usual.For the residents and even faculty reading this, I think there has been an unnecessary rivalry between radonc and uro-onc that predominately only negatively impacts patients. We are a team and I think if we approach the care of our patients as a team we will provi...
In which prostate cancer patients, if any, do you consider adding ADT to adjuvant radiation therapy following prostatectomy?
Two trials (RTOG 9601 and GETUG-AFU 16) have demonstrated a benefit to adding ADT to salvage radiotherapy, and both required a minimum PSA of 0.2 ng/ml or higher. In RTOG 9601, the subgroup of patients who appeared to benefit most from ADT were those with PSA >0.7 ng/ml, suggesting that concurrent A...
Is antiandrogen monotherapy a reasonable option for a patient with high-risk disease getting IMRT (+/- BT boost) who refuses GNRH modulators?
I do use anti-androgen monotherapy as a compromise for patients who refuse LHRH agonists. Many patients walk out the door when LHRH agonists are mentioned. The PSA nadir is not as low with biclutamide as with LHRH agonists. There is experience with biclutamide at 150 mg both in non randomized report...
How do you define PSA progression after salvage or adjuvant prostate fossa radiotherapy?
This is an excellent question which in part mixes tradition, clinical practice, and the conduct of clinical trials both on-going and in the past. Fundamentally, from a clinical stand-point the definition of PSA failure should help manage the patient and improve outcome (prolong life, decrease harm s...
Is long term ADT now the standard of care with salvage prostate bed RT?
The dreaded hormone question...After 40 years of embarking on extremely well designed randomized trials, we still are confused about the who, what, when of ADT. Will RTOG 9601 create a new care standard? As @Dr. First Last said, I think we will see increased utilization. I have been using bicalutami...
What imaging workup should be completed in patients with a detectable PSA following prostatectomy?
The imaging work-up of recurrent prostate cancer is a topic of considerable interest. Our approach at UCLA has been to recommend, at the very least, a multiparametric MRI to evaluate for locoregional recurrence, and we regularly recommend a technetium bone scan as well. That being stated, we have be...